Record drug shortages (≥216 active in the US in 2025) expose limited end-to-end visibility, motivating AI-driven early risk detection and coordinated mitigation across fragmented networks.

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years. In the final part of Pharmaceutical Commerce’s conversation with Will ...

Jessica Lovett explains the importance of being connected to the broader access ecosystem and leveraging partnerships that can provide global insight and intelligence. In the final part of ...

BIOSECURE is catalyzing structural sourcing and manufacturing shifts, prompting reassessment of legacy partnerships and ...

Acting commissioner Kyle Diamantas assumes interim control, prolonging uncertainty until a Senate-confirmed commissioner is installed and governance stabilizes. Elevated leadership churn and perceived ...

President Trump’s Most Favored Nation (MFN) drug pricing proposals are awaiting approval by the U.S. Congress. Passage of the ...

Sources familiar with White House deliberations suggest Makary’s departure is imminent, though neither the White House nor HHS has confirmed or named a successor. Makary’s tenure aligned FDA with MAHA ...

End-to-end reporting of sensor outputs is often mistaken for environmental truth, creating false confidence when dashboards show stability at a single sensing point. Ground truth failures arise from ...

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years. In the second part of Pharmaceutical Commerce’s conversation with Bill McElnea, vice ...

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle. In the second part of Pharmaceutical Commerce’s conversation with Tommy Bramley, ...